Yu U Chen

7091396, Aug 15, 2006

Oct 17, 2001

09/982120

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

The Rockefeller University - New York NY

A01K 67/027
A01K 67/033
C12N 15/63
C12N 5/06
C12N 5/10

800 18, 800 13, 435326, 435325, 435455, 4353201

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

8386304, Feb 26, 2013

May 29, 2008

12/129593

Yu Chen - Irvine CA, US
Ramin Rahbari - Tustin CA, US

G06Q 40/00

705 14, 705 26, 705 27, 725 46, 725 47, 725 39

A environment of server and client systems for revenue generation, where a component is provided for broadcasters to broadcast and/or transmit programming, and where advertisers can create advertisement, and bid for advertising time on the transmitted programming. Advertisers are empowered by the network's ability to perform targeted advertising and/or product placement base on viewer attribute, programming content, and other criteria collected by the environment. Broadcasters are empowered by the network's ability to produce relatively high conversion rate using an viewer interface allowing enabling viewers to perform click-to-buy, click-to-send-lead, and/or click-to-send information, without much disruption to viewing of the transmitted programming. Also disclosed is a business method of generating revenue by utilizing an environment of server and client systems for targeted advertising and/or product placement, where incentives are created by and for broadcasters, advertisers, content providers, creator of the environment, and viewers.

20030049597, Mar 13, 2003

Mar 1, 2001

09/797496

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

C12Q001/00
C12Q001/37
C12N015/87

435/004000, 435/023000, 435/455000

Method for similtaneously quantifying in situ the relationship between an enzyme and its substrate, especially by the use of fluorescence.

20060288430, Dec 21, 2006

Jun 23, 2006

11/474133

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

A01K 67/027

800006000, 800014000

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

20090193530, Jul 30, 2009

Dec 12, 2008

12/316433

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

A01K 67/027
C12N 15/85
C12N 5/06
C07K 16/18

800 6, 800 14, 435328, 5303917

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

62040677, Mar 20, 2001

Jun 17, 1999

9/335457

Sanford M. Simon - New York NY
Melvin S. Schindler - Okemos MI
Yu Chen - New York NY

Board of Trustees Operating Michigan State University - East Lansing MI

G01N 3122
G01N 2180
G01N 3348
C07C21104

436163

The present invention discloses the mechanism of tamoxifen mediated inhibition of acidification. This mechanism information is then used to design methods of identifying compounds that will have the pharmaceutical effect of tamoxifen without the corresponding side-effects.

20190292529, Sep 26, 2019

Jan 25, 2019

16/258477

- New York NY, US
Thomas WIESNER - New York NY, US
Yu CHEN - New York NY, US

Memorial Sloan Kettering Cancer Center - New York NY

C12N 9/12
A61K 31/5377
A61K 31/545
G01N 33/574
A61K 31/4545
C12Q 1/6886
A61K 31/506

The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.

20170183450, Jun 29, 2017

Mar 13, 2017

15/456624

- Duesseldorf, DE
Timothy M. Champagne - Orange CA, US
Yu Chen - Eastvale CA, US
John Killoran - Dublin, IE

C08G 73/02
C08L 79/02

A curable composition is provided, which includes a benzoxazine component; and a cationic catalyst comprised of a lithium cation and an anion comprising a hexahalogenated Group 15 element.